CLDX Q4 2017 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+84.4% YoY

Gross Profit

-$20M-578.9% margin

Operating Income

-$26M-738.6% margin

Net Income

-$4M-111.1% margin

EPS (Diluted)

$-0.41

QoQ Revenue Growth

-11.9%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$316M

Total Liabilities

$79M

Stockholders' Equity

$236M

Cash & Equivalents

$40M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$2M	+84.4%
Gross Profit	-$20M	$2M	-1168.2%
Operating Income	-$26M	-$35M	+26.8%
Net Income	-$4M	-$32M	+88.1%